Tirzepatide (30 mg) is a synthetic 39-amino-acid peptide developed for research into metabolic regulation and energy balance. It mimics two naturally occurring incretin hormones—GLP-1 and GIP—with structural modifications to enhance stability and biological activity.

This peptide includes non-standard amino acids (Aib residues) and a fatty acid side chain, thereby extending its activity in biological systems and enabling prolonged observation in laboratory models. Its molecular formula is C₂₂₅H₃₄₈N₄₈O₆₈ with a molecular weight of approximately 4813.48 g/mol.

In research settings, Tirzepatide is supplied as a lyophilized powder in a 30 mg vial, suitable for receptor-binding assays, metabolic profiling, and in vivo investigations.

Current research focuses on how Tirzepatide influences glucose regulation, appetite control, and body weight dynamics in experimental models.

Tirzepatide (30 mg) Key Features & Specs

• Subcategory: Weight Loss & Metabolic Peptides
• Strength: 30 mg
• CAS: 2023788-19-2
• Chemical Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: 4813.48 g/mol
• Peptide Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20-linker)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
• Synonyms: P1206, LY3298176, tirzepatida, tirzepatidum, OYN3CCI6QE

For laboratory research use only.

Tirzepatide (30 mg) Research Uses

Research on Tirzepatide focuses on its effects on glucose regulation, nutrient handling, and energy balance. It has been studied in both cellular and whole-organism models to explore how incretin-like signaling influences insulin secretion, appetite, and body weight.

In laboratory models, Tirzepatide is used to study the body’s response to nutrient intake, including gastric emptying, glucose absorption, and hormonal signaling after meals. It is also used to investigate its effects on pancreatic function and insulin-producing cells under varying metabolic conditions.

In obesity and metabolic imbalance models, Tirzepatide may influence food intake, fat storage, and energy expenditure. In animal models, outcomes include body weight changes, fat mass distribution, and metabolic markers like glucose, insulin, and lipids.

Additionally, Tirzepatide has been explored in central nervous system studies to understand appetite regulation, particularly in regions related to hunger and satiety. It is used to study integrated metabolic signaling, rather than as a direct therapeutic intervention.

Tirzepatide (30 mg) Insights & Observed Findings

Research shows consistent metabolic effects in various experimental models, with outcomes depending on dose, duration, and study design.

• In rodent studies, repeated dosing (10 nmol/kg) has led to body weight reductions and changes in metabolic markers like insulin and leptin. These studies report shifts in energy balance, reduced food intake, and altered fat mass distribution.
• In feeding behavior models, single doses (0.3 to 30 nmol/kg) produce dose-dependent decreases in food intake, helping to evaluate how incretin signaling influences appetite control.
• Pharmacokinetic studies in animals provide insights into absorption and systemic exposure, showing extended activity due to structural modifications.
• Published literature has documented tirzepatide's pharmacological activity in human clinical studies; however, these findings are cited solely for scientific reference. This product is for laboratory research purposes only and not intended for human administration.
• Gastrointestinal responses at higher exposure levels are commonly observed, consistent with incretin-based mechanisms.

Tirzepatide (30 mg) Handling & Storage

• Store Tirzepatide (30 mg) as a lyophilized powder at –20°C in a sealed container, protected from light and moisture.
• Allow the vial to reach room temperature before opening to reduce condensation.
• Reconstituted solutions should be stored at 2–8°C for short-term use. Aliquoting is recommended to avoid repeated freeze-thaw cycles.
• Proper handling practices are essential to maintain peptide integrity throughout the research process.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. National Center for Biotechnology Information. PubChem Compound Summary for CID 156588324, Tirzepatide. https://pubchem.ncbi.nlm.nih.gov/compound/156588324
2. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
3. Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. doi:10.1073/pnas.2116506119
4. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
5. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. Published 2022 Jul 5. doi:10.3390/molecules27134315